Related Experiment Videos
Stabilization of the pyruvate dehydrogenase E1alpha subunit by dichloroacetate
K J Morten1, M Caky, P M Matthews
1Institute of Molecular Medicine and Department of Clinical Neurology, University of Oxford, John Radcliffe Hospital, Headington, UK.
Neurology
|November 18, 1998
Summary
Dichloroacetate (DCA) treatment slows the degradation of pyruvate dehydrogenase (PDH) E1alpha subunits. This novel mechanism increases PDH activity, offering a new approach for treating lactic acidemia.
Area of Science:
- Biochemistry
- Mitochondrial biology
- Enzyme kinetics
Background:
- Pyruvate dehydrogenase (PDH) deficiency causes neonatal encephalomyopathies and lactic acidosis.
- Dichloroacetate (DCA) is a treatment for PDH deficiency.
- DCA's known mechanism involves increasing the activated state of PDH, but this doesn't explain all treatment responses.
Purpose of the Study:
- To investigate the effect of chronic dichloroacetate (DCA) treatment on pyruvate dehydrogenase (PDH) subunit turnover rates.
- To explore potential novel mechanisms of DCA action in treating lactic acidemia.
Main Methods:
- Utilized pulse-chase experiments in a normal fibroblastic cell line.
- Measured PDH subunit turnover rates before and after 5-day treatment with 5 mM DCA.
Main Results:
- Chronic DCA treatment significantly decreased the degradation rate of the PDH E1alpha subunit (by over twofold).
- DCA treatment led to a selective and progressive increase in total cellular PDH activity (by approximately 150%).
Conclusions:
- Chronic DCA treatment inhibits the degradation of the mitochondrial E1alpha subunit.
- This inhibition represents a novel mechanism contributing to increased maximal PDH complex activity.
- This finding offers a new therapeutic insight for managing lactic acidemia.